Sugi Predict

Sugi Predict / Compounds / SCHEMBL483535

SCHEMBL483535

SCHEMBL483535

CCOC(=O)[C@@H](CCC(=O)c1ccc(OCc2ccccc2)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ BCL2 P10415 1/20 0.49
▸ LTA4H P09960 1/20 0.48
▸ EGFR P00533 4/20 0.48
▸ LMNA P02545 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ CTSK P43235 2/20 0.48
▸ CTSS P25774 1/20 0.48
▸ PTPN1 P18031 1/20 0.47
▸ PPARA Q07869 4/20 0.47
▸ PPARG P37231 3/20 0.47
▸ SYK P43405 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ PPARD Q03181 2/20 0.45
▸ ADRB2 P07550 1/20 0.45
▸ ADRB1 P08588 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28514047 0.94 EGFR (0.50) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL28514045 0.94 EGFR (0.50) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL22362633 0.93 LTA4H (0.53) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL20876893 0.93 LTA4H (0.53) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL311817 0.92 EGFR (0.50) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL22546606 0.92 EGFR (0.50) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL483762 0.92 EGFR (0.50) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL20876849 0.90 PPARA (0.55) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL2714607 0.90 PPARA (0.55) BCL2LTA4HEGFRCTSKCTSS
SCHEMBL2727271 0.90 PPARA (0.55) BCL2LTA4HEGFRCTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153623-B2 Compounds Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153623-B2 Compounds Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153623-B2 Compounds Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153681-B2 Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153681-B2 Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8153681-B2 Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide Convergence Pharmaceuticals Limited (GB) 2012-04-10 — — US disclosed
US-8143306-B2 Methods of treating bipolar disorders Convergence Pharmaceuticals Limited (GB) 2012-03-27 — — US disclosed
US-8143306-B2 Methods of treating bipolar disorders Convergence Pharmaceuticals Limited (GB) 2012-03-27 — — US disclosed
US-8143306-B2 Methods of treating bipolar disorders Convergence Pharmaceuticals Limited (GB) 2012-03-27 — — US disclosed
EP-1934176-B1 QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LTD (GB) 2012-02-01 — — EP disclosed
US-20100105754-A1 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY GLAXO GROUP LIMITED (GB) 2010-04-29 — — US disclosed
US-7655693-B2 Compounds GLAXO GROUP LIMITED (GB) 2010-02-02 — — US disclosed
US-7655693-B2 Compounds GLAXO GROUP LIMITED (GB) 2010-02-02 — — US disclosed
US-20080306122-A1 Novel Compounds Convergence Pharmaceuticals Limited (GB) 2008-12-11 — — US disclosed
US-20080293753-A1 Novel Compounds Convergence Pharmaceuticals Limited (GB) 2008-11-27 — — US disclosed
US-20080280969-A1 Novel Compounds GLAXO GROUP LIMITED 2008-11-13 — — US disclosed
US-20080280969-A1 Novel Compounds GLAXO GROUP LIMITED 2008-11-13 — — US disclosed
WO-2007042239-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed
WO-2007042240-A1 QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed
WO-2007042250-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306122-A1 Novel Compounds CYP11B1, CYP11B2, CYP46A1 ALDH1A1 587/4885MAPT 2920/4885BCL2 3087/4885
US-20080280969-A1 Novel Compounds CYP11B2, CYP46A1, SLC10A1 ALDH1A1 680/4885MAPT 1950/4885BCL2 3715/4885
US-20080293753-A1 Novel Compounds CACNA1E, CACNA1A, SCN1B ALDH1A1 1652/4885MAPT 2335/4885BCL2 2150/4885
US-20100105754-A1 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY SCN5A, SCN1A, SCN7A ALDH1A1 646/4885MAPT 810/4885BCL2 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.